2. Signaling Pathways
  3. GPCR/G Protein
  4. Prostaglandin Receptor
  5. Prostaglandin Receptor Isoform
  6. Prostaglandin Receptor Inhibitor

Prostaglandin Receptor Inhibitor

Prostaglandin Receptor Inhibitors (47):

Cat. No. Product Name Effect Purity
  • HY-108308
    Ibuprofen guaiacol ester
    		Inhibitor 98.49%
    Ibuprofen guaiacol ester (AF 2259; Metoxibutropate) is a potent and orally active prostaglandin synthesis inhibitor. Ibuprofen guaiacol ester has the potential for the research of edema and fever.
  • HY-B1074
    Ethamsylate
    		Inhibitor 99.49%
    Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis..
  • HY-15342A
    Timapiprant sodium
    		Inhibitor 99.61%
    Timapiprant sodium (OC000459 sodium) is a potent, selective, and orally active D prostanoid receptor 2 (DP2, also known as CRTH2) antagonist. Timapiprant sodium (OC000459 sodium) potently displaces [3H] PGD2 from human recombinant DP2 (Ki=13 nM), rat recombinant DP2 (Ki=3 nM), and human native DP2 (Ki=4 nM). Timapiprant sodium (OC000459 sodium) inhibits mast cell activation of Th2 lymphocytes and eosinophils.
  • HY-130223
    11β-Prostaglandin E2
    		Inhibitor ≥99.0%
    11β-Prostaglandin E2 (11β-Dinoprostone), a Prostanoid derivative, inhibits [3H]PGE2 binding to hypothalamic membranes in the rat with a Ki of 53.3 nM.
  • HY-107795
    Benorilate
    		Inhibitor 99.85%
    Benorylate (Salipran) is the esterification product of paracetamol and acetylsalicylic acid. Benorylate has anti-inflammatory, analgesic and antipyretic properties. Benorylate could also inhibit prostaglandin (PG) synthesis.
  • HY-101813
    Laflunimus
    		Inhibitor 99.76%
    Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor.
  • HY-138665
    HHS-0701
    		Inhibitor 98.90%
    HHS-0701, a sulfur-triazole exchange (SuTEx) ligand, is a potent tyrosine-reactive prostaglandin reductase 2 (PTGR2) inhibitor. HHS-0701 blocks PTGR2 metabolism of the lipid substrate 15-Keto-PGE2.
  • HY-114564
    Satigrel
    		Inhibitor 99.85%
    Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC50: 0.081 μM) and PGHS2 (IC50: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC50: 15.7 μM, 39.8 μM and 62.4 μM, respectively).
  • HY-101438
    Darbufelone
    		Inhibitor ≥98.0%
    Darbufelone is a dual inhibitor of cellular PGF2α and LTB4 production. Darbufelone potently inhibits PGHS-2 (IC50= 0.19 μM) but is much less potent with PGHS-1 (IC50=20 μM).
  • HY-Z7721
    (Rac)-Beraprost sodium
    		Inhibitor
    (Rac)-Beraprost ((Rac)-ML 1229) sodium is a racemic isomer of Beraprost sodium (HY-13569A). Beraprost sodium is an orally active prostacyclin analog that inhibits the release of Ca2+ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost sodium has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis.
  • HY-106874B
    rel-Delequamine
    		Inhibitor
    rel-Delequamine (rel-RS-15385-197) is an orally active, brain-penetrant, potent and selective M2-adrenoceptor antagonist and α2-adrenoceptor antagonist. rel-Delequamine has a pKi of 9.45 for α2-adrenoceptors in the rat cortex. rel-Delequamine augments K+-evoked release of noradrenaline with an EC50 of 1 nM.
  • HY-W009706B
    Alclofenac (lysinate)
    		Inhibitor
    Alclofenac lysinate is a non-steroidal anti-inflammatory agent (NSAID). Alclofenac lysinate is a prostaglandin H2 synthase inhibitor. Alclofenac lysinate can be used for rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis research.
  • HY-129199
    U-51605
    		Inhibitor
    U-51605 is a platelet aggregation inhibitor and inhibits thromboxane synthesis. U-51605 is also a prostaglandin I2 synthase inhibitor and can inhibit the retinal vasodilation response induced by NO donors (such as NOR3).
  • HY-N11566
    (+)-Oxypeucedanin methanolate
    		Inhibitor
    (+)-Oxypeucedanin methanolate (compound 9) is a natural compound with inhibitory effect on prostaglandin E2 production.
  • HY-134511
    15(S)-HpEPE
    		Inhibitor
    15(S)-HpEPE is a product of lipoxygenase hydrolysis of unsaturated fatty acids (PUFA) and is a potential inhibitor of prostaglandin H synthase 2 (PGHS-2). 15(S)-HpEPE can downregulate the expression of PGHS-2.
  • HY-107320
    Amtolmetin guacil
    		Inhibitor
    Amtolmetin guacil is an effective nonsteroidal anti-Inflammatory agent with pain-relieving effects. Amtolmetin guacil inhibits prostaglandin synthesis and cyclooxygenase (COX). Amtolmetin guacil can stimulate capsaicin receptors present on the gastrointestinal wall and also releases gastroprotective nitric oxide (NO). Amtolmetin guacil can be used to research knee osteoarthritis.
  • HY-125970
    CRTh2 antagonist 2
    		Inhibitor 99.78%
    CRTh2 antagonist 2 is selective and potent CRTH2 antagonist extracted from patent US20140148470A1, compound Example 1, has an IC50 of ≤10 nM. CRTh2 antagonist 2 can be used in research of androgenic alopecia.
  • HY-155321
    NXT-10796
    		Inhibitor
    NXT-10796 is orally active, intestinally restricted EP4 receptor agonist.
  • HY-N0607R
    Ginsenoside Ro (Standard)
    		Inhibitor
    Ginsenoside Ro (Standard) is the analytical standard of Ginsenoside Ro. This product is intended for research and analytical applications. Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155 μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.
  • HY-113444
    Prostaglandin D3
    		Inhibitor
    Prostaglandin D3 (PGD3) is a prostaglandin that acts as an inhibitor of platelet aggregation and a modulator of autonomic neurotransmission in humans.